Indian drugmaker faces LCIA claim over covid vaccine
A Seattle biotech company is bringing an LCIA claim against its Indian former business partner amid a US$950 million dispute over alleged theft of technology used to develop covid-19 vaccines.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Global Arbitration Review (GAR) is the online home for international arbitration specialists, telling them everything they need to know about all the developments that matter.